Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Integration of biomarkers and...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Integration of biomarkers and clinical characteristics provides the best method for identifying patients with MODY
Bibliographic Details
Main Authors:
Shields, B
,
McDonald, T
,
Owen, K
,
Malecki, M
,
Besser, R
,
Jones, A
,
Ellard, S
,
Hattersley, A
Format:
Journal article
Published:
2012
Holdings
Description
Similar Items
Staff View
Similar Items
High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
by: McDonald, T, et al.
Published: (2011)
High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
by: McDonald, T, et al.
Published: (2011)
Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes.
by: McDonald, T, et al.
Published: (2012)
Response to Comment on: McDonald et al. High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes. Diabetes Care 2011;34:1860-1862.
by: McDonald, T, et al.
Published: (2011)
Cystatin C is not a good candidate biomarker for HNF1A-MODY.
by: Nowak, N, et al.
Published: (2013)